323 related articles for article (PubMed ID: 11127947)
1. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
Li C; Newman RA; Wu QP; Ke S; Chen W; Hutto T; Kan Z; Brannan MD; Charnsangavej C; Wallace S
Cancer Chemother Pharmacol; 2000; 46(5):416-22. PubMed ID: 11127947
[TBL] [Abstract][Full Text] [Related]
2. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.
Li C; Ke S; Wu QP; Tansey W; Hunter N; Buchmiller LM; Milas L; Charnsangavej C; Wallace S
Clin Cancer Res; 2000 Jul; 6(7):2829-34. PubMed ID: 10914731
[TBL] [Abstract][Full Text] [Related]
3. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
5. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.
Oldham EA; Li C; Ke S; Wallace S; Huang P
Int J Oncol; 2000 Jan; 16(1):125-32. PubMed ID: 10601557
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate.
Li C; Ke S; Wu QP; Tansey W; Hunter N; Buchmiller LM; Milas L; Charnsangavej C; Wallace S
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1119-26. PubMed ID: 11072171
[TBL] [Abstract][Full Text] [Related]
7. Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability.
Milas L; Mason KA; Hunter N; Li C; Wallace S
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):707-12. PubMed ID: 12573758
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant.
Shikanov A; Shikanov S; Vaisman B; Golenser J; Domb AJ
Int J Pharm; 2008 Jun; 358(1-2):114-20. PubMed ID: 18406086
[TBL] [Abstract][Full Text] [Related]
12. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
Gustafson DL; Long ME; Bradshaw EL; Merz AL; Kerzic PJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):248-54. PubMed ID: 15856231
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of radioresponse by polymer-drug conjugates.
Ke S; Milas L; Charnsangavej C; Wallace S; Li C
J Control Release; 2001 Jul; 74(1-3):237-42. PubMed ID: 11489500
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.
Zou Y; Wu QP; Tansey W; Chow D; Hung MC; Charnsangavej C; Wallace S; Li C
Int J Oncol; 2001 Feb; 18(2):331-6. PubMed ID: 11172600
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice].
Huo MR; Zhou JP; Wei Y; Lü L
Yao Xue Xue Bao; 2006 Sep; 41(9):867-72. PubMed ID: 17111835
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
Singer JW
J Control Release; 2005 Dec; 109(1-3):120-6. PubMed ID: 16297482
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line.
Multani AS; Li C; Ozen M; Yadav M; Yu DF; Wallace S; Pathak S
Anticancer Res; 1997; 17(6D):4269-74. PubMed ID: 9494519
[TBL] [Abstract][Full Text] [Related]
19. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
